pharmadog
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search

calendar

129 catalysts · 4,970 phase readout · 2,346 8k filing · 287 earnings · 274 pdufa · 129 phase 2 completion · 61 phase 1 completion

★ save view↓export CSV
next 91 dayslessmore
MonWedFri
2026-07-27: 17 catalysts2026-07-28: 4 catalysts2026-07-29: 12 catalysts2026-07-30: 12 catalysts2026-07-31: 3 catalysts2026-08-01: 0 catalysts2026-08-02: 0 catalysts2026-08-03: 4 catalysts2026-08-04: 12 catalysts2026-08-05: 14 catalysts2026-08-06: 10 catalysts2026-08-07: 1 catalyst2026-08-08: 0 catalysts2026-08-09: 0 catalysts2026-08-10: 1 catalyst2026-08-11: 1 catalyst2026-08-12: 1 catalyst2026-08-13: 0 catalysts2026-08-14: 0 catalysts2026-08-15: 0 catalysts2026-08-16: 0 catalysts2026-08-17: 0 catalysts2026-08-18: 1 catalyst2026-08-19: 0 catalysts2026-08-20: 0 catalysts2026-08-21: 0 catalysts2026-08-22: 0 catalysts2026-08-23: 0 catalysts2026-08-24: 0 catalysts2026-08-25: 0 catalysts2026-08-26: 0 catalysts2026-08-27: 0 catalysts2026-08-28: 0 catalysts2026-08-29: 0 catalysts2026-08-30: 0 catalysts2026-08-31: 0 catalysts2026-09-01: 1 catalyst2026-09-02: 0 catalysts2026-09-03: 0 catalysts2026-09-04: 0 catalysts2026-09-05: 0 catalysts2026-09-06: 0 catalysts2026-09-07: 0 catalysts2026-09-08: 0 catalysts2026-09-09: 0 catalysts2026-09-10: 0 catalysts2026-09-11: 0 catalysts2026-09-12: 0 catalysts2026-09-13: 0 catalysts2026-09-14: 0 catalysts2026-09-15: 0 catalysts2026-09-16: 0 catalysts2026-09-17: 0 catalysts2026-09-18: 0 catalysts2026-09-19: 0 catalysts2026-09-20: 0 catalysts2026-09-21: 0 catalysts2026-09-22: 0 catalysts2026-09-23: 0 catalysts2026-09-24: 0 catalysts2026-09-25: 0 catalysts2026-09-26: 0 catalysts2026-09-27: 0 catalysts2026-09-28: 0 catalysts2026-09-29: 0 catalysts2026-09-30: 0 catalysts2026-10-01: 0 catalysts2026-10-02: 0 catalysts2026-10-03: 0 catalysts2026-10-04: 0 catalysts2026-10-05: 0 catalysts2026-10-06: 0 catalysts2026-10-07: 0 catalysts2026-10-08: 0 catalysts2026-10-09: 0 catalysts2026-10-10: 0 catalysts2026-10-11: 0 catalysts2026-10-12: 0 catalysts2026-10-13: 0 catalysts2026-10-14: 0 catalysts2026-10-15: 0 catalysts2026-10-16: 0 catalysts2026-10-17: 0 catalysts2026-10-18: 0 catalysts2026-10-19: 0 catalysts2026-10-20: 1 catalyst2026-10-21: 0 catalysts2026-10-22: 1 catalyst2026-10-23: 0 catalysts2026-10-24: 0 catalysts2026-10-25: 0 catalysts
view
agendamonth
show past →
sort
soonestlatesttypesponsoralpha
type: phase 2 completion×clear all
type
  • phase readout4,970
  • 8k filing2,346
  • earnings287
  • pdufa274
  • phase 2 completion129
  • phase 1 completion61
phase 1 initiation
32
  • phase 1 2 completion28
  • phase 0 trial completion22
  • phase 2 initiation16
  • therapy area
    • Oncology28
    • Cardiology10
    • Women's Health8
    • Immunology8
    • Infectious Disease5
    • Dermatology5
    • Pulmonology5
    • Pain3
    • Ophthalmology2

    Week of Apr 27, 2026

    50
    ›Apr 28, 2026phase 2 completion91d agoChangzhou Hengbang Pharmaceutical Co Ltd — HS-10374 (Phase II Trial Completion)HS-10374

    Therapy area: Musculoskeletal Disorders. Indication: Psoriatic Arthritis

    full page →HS-10374 →source: globaldata
    ›Apr 28, 2026phase 2 completion91d agoKS Hegde Medical Academy — fentanyl (Phase II Trial Completion)fentanyl ER

    Therapy area: Hormonal Disorders. Indication: Endocrine Gland Disorders

    full page →fentanyl ER →source: globaldata
    ›Apr 28, 2026phase 2 completion91d agoInonu University — albumin gel- and platelet- rich fibrin (Phase II Trial Completion)albumin gel- and platelet- rich fibrin

    Therapy area: Immunology, Mouth and Dental Disorders. Indication: Inflammation, Periodontal Disease, Periodontitis

    full page →albumin gel- and platelet- rich fibrin →source: globaldata
    ›Apr 28, 2026phase 2 completion91d agoUmraniye Research Hospital — bupivacaine (Phase II Trial Completion)bupivacaine

    Therapy area: Central Nervous System. Indication: Post-Operative Pain

    full page →bupivacaine →source: globaldata
    ›Apr 28, 2026phase 2 completion91d agoAnanta Institute of Medical Sciences and Research Centre — levobupivacaine (Phase II Trial Completion)levobupivacaine

    Therapy area: Central Nervous System, Gastrointestinal. Indication: Inguinal Hernia, Post-Operative Pain

    full page →levobupivacaine →source: globaldata
    ›Apr 28, 2026phase 2 completion91d agoGastroenterological Association of Thailand — metadoxine (Phase II Trial Completion)metadoxine

    Therapy area: Gastrointestinal. Indication: Metabolic and Alcohol-Associated Liver Disease (MetALD), Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD or NAFLD)

    full page →metadoxine →source: globaldata
    ›Apr 28, 2026phase 2 completion91d agoTianjin Medical University Cancer Institute and Hospital — AG [gemcitabine + nab-paclitaxel] (Phase II Trial Completion)AG [gemcitabine + nab-paclitaxel]

    Therapy area: Oncology. Indication: Pancreatic Cancer

    full page →AG [gemcitabine + nab-paclitaxel] →source: globaldata
    ›Apr 28, 2026phase 2 completion91d agoHackensack Meridian Health Inc — carboplatin (Phase II Trial Completion)Carboplatin Pfizer

    Therapy area: Oncology. Indication: Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma

    full page →Carboplatin Pfizer →source: globaldata
    ›Apr 28, 2026phase 2 completion91d agoTamilnadu Government Dental College and Hospital — metformin (Phase II Trial Completion)metformin

    Therapy area: Mouth and Dental Disorders. Indication: Unspecified Mouth and Dental Disorders

    full page →metformin →source: globaldata
    ›Apr 28, 2026phase 2 completion91d agoArdabil University of Medical Sciences — chorionic gonadotropin (Phase II Trial Completion)chorionic gonadotropin

    Therapy area: Women's Health. Indication: Female Infertility

    full page →chorionic gonadotropin →source: globaldata
    ›Apr 28, 2026phase 2 completion91d agoShanghai Pulmonary Hospital — undisclosed programmed cell death protein 1 inhibitor (Phase II Trial Completion)undisclosed programmed cell death protein 1 inhibitor

    Therapy area: Oncology. Indication: Non-Small Cell Lung Cancer

    full page →undisclosed programmed cell death protein 1 inhibitor →source: globaldata
    ›Apr 28, 2026phase 2 completion91d agoAl-Mustansiriya University — platelet rich fibrin (Phase II Trial Completion)platelet rich fibrin

    Therapy area: Mouth and Dental Disorders. Indication: Periodontitis

    full page →platelet rich fibrin →source: globaldata
    ›Apr 28, 2026phase 2 completion91d agoWest China Hospital of Stomatology — dexamethasone (Phase II Trial Completion)dexamethasone

    Therapy area: Mouth and Dental Disorders. Indication: Aphthous Ulcers (Canker Sores)

    full page →dexamethasone →source: globaldata
    ›Apr 28, 2026phase 2 completion91d agoUniversity of Sao Paulo General Hospital — iloprost (Phase II Trial Completion)iloprost

    Therapy area: Cardiovascular. Indication: Pulmonary Arterial Hypertension

    full page →iloprost →source: globaldata
    ›Apr 29, 2026phase 2 completion90d agoCARsgen Therapeutics Holdings Ltd — CT-0594CP CAR-T Cells (Phase II Trial Completion)CT-0594CP CAR-T Cells

    Therapy area: Oncology. Indication: Multiple Myeloma (Kahler Disease), Plasma Cell Neoplasm, Refractory Multiple Myeloma, Relapsed Multiple Myeloma

    full page →CT-0594CP CAR-T Cells →source: globaldata
    ›Apr 29, 2026phase 2 completion90d agoTexas Christian University — Alii Supplement (Phase II Trial Completion)Alii Supplement

    Therapy area: Nutritional Disorders. Indication: Unspecified Nutritional Disorders

    full page →Alii Supplement →source: globaldata
    ›Apr 29, 2026phase 2 completion90d agoMassachusetts Eye and Ear Infirmary — N-acetylcysteine (Phase II Trial Completion)N-acetylcysteine

    Therapy area: Ophthalmology. Indication: Cataract, Fuchs Endothelial Corneal Dystrophy (FECD)

    full page →N-acetylcysteine →source: globaldata
    ›Apr 29, 2026phase 2 completion90d agoNational Heart Lung and Blood Institute — danazol (Phase II Trial Completion)danazol

    Therapy area: Gastrointestinal, Genetic Disorders, Hematological Disorders, Respiratory. Indication: Cytopenia, Liver Fibrosis, Mutational Disorders, Pulmonary Fibrosis

    full page →danazol →source: globaldata
    ›Apr 29, 2026phase 2 completion90d agoSaraswati Dhanwantari Dental College and Hospital Parbhani — (amoxicillin + clavulanic acid) (Phase II Trial Completion)(amoxicillin + clavulanic acid)

    Therapy area: Infectious Disease, Mouth and Dental Disorders. Indication: Periodontitis, Unspecified Infectious Diseases

    full page →(amoxicillin + clavulanic acid) →source: globaldata
    ›Apr 29, 2026phase 2 completion90d agoBangalore Medical College and Research Institute — dinoprostone (Phase II Trial Completion)dinoprostone ER

    Therapy area: Dermatology. Indication: Vitiligo

    full page →dinoprostone ER →source: globaldata
    ›Apr 29, 2026phase 2 completion90d agoNational Institute of Unani Medicine — unani medicine (Phase II Trial Completion)unani medicine

    Therapy area: Women's Health. Indication: Menorrhagia

    full page →unani medicine →source: globaldata
    ›Apr 30, 2026phase 2 completion89d agoUsynova Pharmaceuticals Ltd — UA-021 (Phase II Trial Completion)UA-021

    Therapy area: Immunology. Indication: Plaque Psoriasis (Psoriasis Vulgaris), Psoriasis

    full page →UA-021 →source: globaldata
    ›Apr 30, 2026phase 2 completion89d agoCairo University — lidocaine (Phase II Trial Completion)LIDOCAINE

    Therapy area: Central Nervous System. Indication: Post-Operative Pain

    full page →LIDOCAINE →source: globaldata
    ›Apr 30, 2026phase 2 completion89d agoVeer Chandra Singh Garhwali Government Medical Science and Research Institute — bupivacaine (Phase II Trial Completion)bupivacaine

    Therapy area: Ear Nose Throat Disorders. Indication: Otitis Media

    full page →bupivacaine →source: globaldata
    ›Apr 30, 2026phase 2 completion89d agoUniversity of Benin Teaching Hospital — doxycycline (Phase II Trial Completion)doxycycline ER

    Therapy area: Women's Health. Indication: Unspecified Gynecological Disorders

    full page →doxycycline ER →source: globaldata
    ›Apr 30, 2026phase 2 completion89d agoVaidya Yagya Dutt Sharma Ayurvedic P. G. Mahavidhyalaya — ayurvedic medicine (Phase II Trial Completion)ayurvedic medicine

    Therapy area: Dermatology. Indication: Burns

    full page →ayurvedic medicine →source: globaldata
    ›Apr 30, 2026phase 2 completion89d agoGandhi Medical College & Hospital — dexmedetomidine (Phase II Trial Completion)dexmedetomidine

    Therapy area: Oncology. Indication: Malignant Neoplasms

    full page →dexmedetomidine →source: globaldata
    ›Apr 30, 2026phase 2 completion89d agoZhejiang Provincial People's Hospital — telitacicept (Phase II Trial Completion)telitacicept

    Therapy area: Immunology. Indication: Rheumatoid Arthritis

    full page →telitacicept →source: globaldata
    ›Apr 30, 2026phase 2 completion89d agoDalian Municipal Central Hospital — dexamethasone (Phase II Trial Completion)dexamethasone

    Therapy area: Central Nervous System. Indication: Post-Operative Pain

    full page →dexamethasone →source: globaldata
    ›Apr 30, 2026phase 2 completion89d agoSmt.B.K.Shah Medical Institute & Research Centre & Dhiraj Hospital — dexmedetomidine (Phase II Trial Completion)dexmedetomidine

    Therapy area: Central Nervous System. Indication: Sedation

    full page →dexmedetomidine →source: globaldata
    ›Apr 30, 2026phase 2 completion89d agoKSO Corp — undisclosed plant extract (Phase II Trial Completion)undisclosed plant extract

    Therapy area: Genito Urinary System. Indication: Unspecified Genito Urinary Disorders

    full page →undisclosed plant extract →source: globaldata
    ›Apr 30, 2026phase 2 completion89d agoThe First Affiliated Hospital of Guangxi Medical University — fospropofol disodium (Phase II Trial Completion)fospropofol disodium

    Therapy area: Central Nervous System. Indication: Sedation

    full page →fospropofol disodium →source: globaldata
    ›Apr 30, 2026phase 2 completion89d agoQinghai Provincial Xining Third People's Hospital — amoxicillin (Phase II Trial Completion)amoxicillin

    Therapy area: Gastrointestinal, Infectious Disease. Indication: Gastritis, Helicobacter pylori Infections

    full page →amoxicillin →source: globaldata
    ›Apr 30, 2026phase 2 completion89d agoQilu Pharmaceutical Co Ltd — iruplinalkib (Phase II Trial Completion)iruplinalkib

    Therapy area: Oncology. Indication: Non-Small Cell Lung Cancer

    full page →iruplinalkib →source: globaldata
    ›Apr 30, 2026phase 2 completion89d agoTufts Medical Center — phytonadione (Phase II Trial Completion)PHYTONADIONE

    Therapy area: Musculoskeletal Disorders. Indication: Osteoarthritis

    full page →PHYTONADIONE →source: globaldata
    ›Apr 30, 2026phase 2 completion89d agoDanone Research & Innovation — (prebiotics + probiotic + protein blend + micronutrient blend) (Phase II Trial Completion)(prebiotics + probiotic + protein blend + micronutrient blend)

    Therapy area: Central Nervous System, Metabolic Disorders. Indication: Ageing, Unspecified Psychiatric Disorders

    full page →(prebiotics + probiotic + protein blend + micronutrient blend) →source: globaldata
    ›Apr 30, 2026phase 2 completion89d agoNational Health and Medical Research Council — docosahexaenoic acid (Phase II Trial Completion)docosahexaenoic acid

    Therapy area: Women's Health. Indication: Labor And Delivery

    full page →docosahexaenoic acid →source: globaldata
    ›Apr 30, 2026phase 2 completion89d agoChildren’s Hospital of Chongqing Medical University — iKids-Growth (Phase II Trial Completion)iKids-Growth

    Therapy area: Hormonal Disorders. Indication: Shox Deficiency

    full page →iKids-Growth →source: globaldata
    ›Apr 30, 2026phase 2 completion89d agoRegeneron Pharmaceuticals Inc — cemiplimab (Phase II Trial Completion)cemiplimab

    Therapy area: Oncology. Indication: Adenocarcinoma, Colon Cancer, Colorectal Cancer

    full page →cemiplimab →source: globaldata
    ›Apr 30, 2026phase 2 completion89d agoIntas Pharmaceuticals Ltd — olaparib (Phase II Trial Completion)olaparib

    Therapy area: Oncology. Indication: Breast Cancer, Castration-Resistant Prostate Cancer (CRPC), Epithelial Ovarian Cancer, Fallopian Tube Cancer, Metastatic Breast Cancer, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Peritoneal Cancer, Solid Tumor

    full page →olaparib →source: globaldata
    ›Apr 30, 2026phase 2 completion89d agoGuy's and St Thomas' NHS Foundation Trust — autologous regulatory T cells (Phase II Trial Completion)autologous regulatory T cells

    Therapy area: Genito Urinary System, Immunology. Indication: End-Stage Kidney Disease (End-Stage Renal Disease or ESRD), Kidney Transplant Rejection

    full page →autologous regulatory T cells →source: globaldata
    ›Apr 30, 2026phase 2 completion89d agoMerck & Co Inc — pembrolizumab (Phase II Trial Completion)pembrolizumab

    Therapy area: Oncology. Indication: Glioblastoma Multiforme (GBM), Gliosarcoma

    full page →pembrolizumab →source: globaldata
    ›Apr 30, 2026phase 2 completion89d agoAustralasian Gastro-Intestinal Trials Group — valproate sodium (Phase II Trial Completion)VALPROATE SODIUM

    Therapy area: Oncology. Indication: Colorectal Cancer, Metastatic Colorectal Cancer

    full page →VALPROATE SODIUM →source: globaldata
    ›Apr 30, 2026phase 2 completion89d agoBrigham and Women's Hospital — dupilumab (Phase II Trial Completion)dupilumab

    Therapy area: Ear Nose Throat Disorders, Respiratory. Indication: Asthma, Nasal Polyps (Nasal Polyposis), Rhinosinusitis

    full page →dupilumab →source: globaldata
    ›Apr 30, 2026phase 2 completion89d agoZhejiang University Hospital One — serplulimab (Phase II Trial Completion)serplulimab

    Therapy area: Oncology. Indication: Adenocarcinoma Of The Gastroesophageal Junction, Gastric Cancer

    full page →serplulimab →source: globaldata
    ›Apr 30, 2026phase 2 completion89d agoMerck & Co Inc — tulisokibart (Phase II Trial Completion)tulisokibart

    Therapy area: Immunology, Respiratory. Indication: Diffuse Cutaneous Systemic Sclerosis, Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease), Systemic Sclerosis (Scleroderma)

    full page →tulisokibart →source: globaldata
    ›Apr 30, 2026phase 2 completion89d agoThe National Institute of Diabetes and Digestive and Kidney Diseases — undisclosed anti-diuretics (Phase II Trial Completion)undisclosed anti-diuretics

    Therapy area: Genito Urinary System. Indication: End-Stage Kidney Disease (End-Stage Renal Disease or ESRD)

    full page →undisclosed anti-diuretics →source: globaldata
    ›Apr 30, 2026phase 2 completion89d agoASST Centro Specialistico Ortopedico Traumatologico Gaetano Pini — dexamethasone (Phase II Trial Completion)dexamethasone

    Therapy area: Central Nervous System, Musculoskeletal Disorders. Indication: Bone Fracture, Post-Operative Pain

    full page →dexamethasone →source: globaldata
    ›Apr 30, 2026phase 2 completion89d agoGerman Sport University Cologne — polyphenol-rich cocoa extract (Phase II Trial Completion)polyphenol-rich cocoa extract

    Therapy area: Cardiovascular. Indication: Idiopathic (Essential) Hypertension

    full page →polyphenol-rich cocoa extract →source: globaldata
    ›Apr 30, 2026phase 2 completion89d agoGuangzhou Panyu Central Hospital — aumolertinib mesylate (Phase II Trial Completion)aumolertinib mesylate

    Therapy area: Oncology. Indication: Lung Adenocarcinoma, Non-Small Cell Lung Cancer

    full page →aumolertinib mesylate →source: globaldata
    ← prev
    page 1 of 3
    next →
    $REGN672.60+2.53%
    $MRK131.40+0.25%
    $MRK131.40+0.25%